Companies /Healthcare

Agilent Technologies Inc

NYSE: A Diagnostics & Research
$157.88
â–² $2.80 (+1.80%) today
Markets open · 12:51pm ET

Q3 2025 Earnings

Reported Aug 27, 2025, 4:06pm ET · SEC source
$1.37
Beat +0.17%
EPS · est. $1.37
$1.7B
Beat +4.32%
Revenue · est. $1.7B
+0.0%
Beating market
A vs S&P since report
2 quarters
Consecutive EPS beats

Market Reaction

% change · around the report
−3%0+3%Aug 27Aug 28report 4:06pm ETearnings+0.4%+3.3%
−3%0+3%Aug 27Aug 28earnings+0.4%+3.3%
A +3.3%S&P 500 +0.4%
−3%0+3%Aug 27Aug 28report 4:06pm ETearnings+0.6%+3.3%
−3%0+3%Aug 27Aug 28earnings+0.6%+3.3%
A +3.3%NASDAQ +0.6%
0+3%+6%+9%Aug 26Sep 4report 4:06pm ETearnings+0.5%+8.4%
0+3%+6%+9%Aug 26Sep 4earnings+0.5%+8.4%
A +8.4%S&P 500 +0.5%
0+4%+8%Aug 26Sep 4report 4:06pm ETearnings+0.7%+8.4%
0+4%+8%Aug 26Sep 4earnings+0.7%+8.4%
A +8.4%NASDAQ +0.7%
+5.28%
Day of report
+0.56%
Next session
+3.03%
One week
+2.71%
30 days

S&P 500 over the same 30 days: +2.66%.

Did A Beat Earnings? Q3 2025 Results

Agilent Technologies capped its fifth consecutive quarter of sequential core-revenue acceleration with a clean beat across both top and bottom lines in fiscal Q3 2025, reinforcing the narrative that its Ignite Transformation initiative is delivering tangible results. Revenue climbed 10.1% year-over-year to $1.74 billion, ahead of the $1.67 billion consensus by 4.32%, while non-GAAP EPS of $1.37 edged past the $1.37 estimate, modest in percentage terms but meaningful given the quarter unfolded entirely under a volatile tariff backdrop. The outperformance was broad-based, with all three business groups posting growth; the Life Sciences and Diagnostics Markets Group led the way at 14% reported revenue growth, even as margin pressures emerged from rising input costs. CEO Padraig McDonnell credited the company's operational agility for navigating the tariff environment without derailing momentum. Looking ahead, Agilent lifted its full-year fiscal 2025 revenue outlook to $6.91 billion to $6.93 billion, with non-GAAP EPS now guided to $5.56 to $5.59, and Q4 revenue expected between $1.82 billion and $1.84 billion, signaling continued confidence in the recovery's durability.

Key Takeaways
  • Fifth consecutive quarter of sequential core-revenue acceleration
  • All three business groups grew year-over-year
  • All regions and two largest end markets contributed to growth
  • Ignite Transformation driving profitable growth and operational excellence
  • Core revenue growth of 6.1% excluding currency and M&A impacts

“Our third-quarter performance, which marks our fifth consecutive quarter of sequential core-revenue acceleration, is a testament to the success of our Ignite Transformation and our laser-like focus on profitable growth and operational excellence.”

Agilent Technologies CEO, on the earnings call

Forward Guidance & Outlook

Agilent raised its full-year fiscal 2025 revenue outlook to a range of $6.91 billion to $6.93 billion, representing reported growth of 6.2% to 6.5% and core growth of 4.3% to 4.6%. Full-year non-GAAP EPS is expected in the range of $5.56 to $5.59. For Q4 FY2025, revenue is expected between $1.822 billion and $1.842 billion, representing 7.1% to 8.3% reported growth and 4.8% to 6.0% core growth. Q4 non-GAAP EPS is expected in the range of $1.57 to $1.60 per share. The outlook is based on forecasted currency exchange rates.

A YoY Financials

Q3 2025 vs Q3 2024 · SEC filings Q3 2024 Q3 2025
$0$500.0M$1.0B$1.5B$1.6B$1.7BRevenue$855.0M$888.0MGross Profit$333.0M$360.0MOperating Income$282.0M$336.0MNet Income
$0$500.0M$1.0B$1.5BRevenueGross ProfitOperating IncomeNet Income

A Revenue by Segment

Agilent CrossLab Group$744.0M+8.0%
Life Sciences and Diagnostics Markets Group$670.0M+14.0%
Applied Markets Group$324.0M+7.0%

Figures from SEC filings and company reports. Not investment advice.